| Name | Prasugrel |
| Description | Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS. |
| In vitro | Prasugrel has a faster, higher and more reliable platelet aggregation inhibitory effect than clopidogrel and is metabolized in vivo to an active metabolite with selective P2Y(12) antagonistic activity. |
| In vivo | Prasugrel has a faster, higher and more reliable platelet aggregation inhibitory effect than clopidogrel and is metabolized in vivo to an active metabolite with selective P2Y(12) antagonistic activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (120.5 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.36 mM), Sonication is recommended.
|
| Keywords | Prasugrel | platelet | PCR-4099 | PCR4099 | P2YReceptor | P2Y12 | P2Y Receptor | P2Y | metabolite | LY-640315 | LY 640315 | Inhibitor | inhibit | CS747 | CS 747 | antiplatelet | aggregation | ADP | active |
| Inhibitors Related | Clopidogrel | Prasugrel Hydrochloride | PSB-16133 sodium | Uridine 5′-diphosphoglucose disodium salt | Regrelor disodium | (±) Clopidogrel hydrogen sulfate | Clopidogrel hydrogen sulfate | Uridine-5'-diphosphate disodium salt | N6-(4-Hydroxybenzyl)adenosine | Ticagrelor | Diquafosol tetrasodium | cangrelor tetrasodium |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
